Table 1.
Study and patient characteristics of the included studies.
| Author | Year | Study characteristics | Patient characteristics | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Country | Study design | Prevalence of PLNMs | No. of extracted lymph node | Reference standard | No. of patients | Age (median, range) | PSA (median, range) | D’Amico risk stratification | ||
| Frumer et al. (28) | 2020 | Israel | Retro | 13.5% | Median 9 Range 6–14 |
PLND | 89 | 67 (64–70) | 8.5 (5–15) | Intermediate 40; high risk 49 |
| Franklin et al. (32) | 2020 | Australia | Retro | 24.5% | Median 16 Range 1–53 |
PLND | 233 | 68 (48–81) | 7.4 (1.5–72.0) | Low risk 2; intermediate 90; high risk 141 |
| Kulkarni et al. (26) | 2020 | India | Retro | 45.7% | NA | PLND | 35 | NA | NA | Intermediate and high risk |
| Pallavi et al. (31) | 2020 | India | Pro | 24.1% | NA | NA | 29 | NA | NA | NA |
| Van Leeuwen et al. (24) | 2019 | Netherlands and Australia | Retro | 36.4% | Median 16 Range 12–21 |
ePLND | 140 | NA | 9.4 | Intermediate 30; high risk 110 |
| Yilmaz et al. (23) | 2019 | Turkey | Retro | 20.0% | NA | rPLND | 10 | NA | NA | Low risk 3; intermediate 15; high risk 6 |
| Berger et al. (21) | 2018 | Australia | Retro | 4% | Median 12 Range 3–22 |
PLND | 50 | 649 ± 5.6 | 10.6 ± 8.1 | NA |
| Gupta et al. (20) | 2017 | India | Retro | 58.3% | Median 20 | ePLND | 12 | 61 (46–76) | 24.3 (8.7–200.6) | High risk 12 |
| Zhang et al. (19) | 2017 | China | Retro | 35.7% | Median 7 Range 2–15 |
PLND | 42 | 69 (55–82) | 37.25 (7.2–348.) | Intermediate 17; high risk 25 |
NA, not available.